Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines, Inc. (RVMD)
:RVMD
RVMD Stock Chart & Stats
$61.38
$0.52(1.17%)
At close: 4:00 PM EST
$61.38
$0.52(1.17%)
Day’s Range― - ―
52-Week Range$29.17 - $63.15
Previous CloseN/A
Volume180.68K
Average Volume (3M)2.22M
Market Cap
$11.87B
Enterprise Value$7.06B
Total Cash (Recent Filing)$1.93B
Total Debt (Recent Filing)$158.46M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Mar 02, 2026EPS Estimate
-1.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.61
Shares Outstanding193,319,810
10 Day Avg. Volume2,363,631
30 Day Avg. Volume2,224,127
Financial Highlights & Ratios
PEG Ratio1.69
Price to Book (P/B)3.24
Price to Sales (P/S)0.00
P/FCF Ratio-12.92
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-17.76
Enterprise Value/Ebitda-6.90
Forecast
1Y Price Target
$79.76Price Target Upside29.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-5.36
Revenue Forecast (FY)$5.87M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentRevolution Medicines' daraxonrasib maintains one of the best-in-class profiles to date in both PDAC and NSCLC, with additional optionality from combinations and mutant-selective assets.
Financial PositionRevolution ended 3Q25 with approximately $1.93 billion in cash and cash equivalents, providing an operational runway into 2H27.
Regulatory AccelerationThe CNPV significantly shortens the review period, offering clear advantages to Revolution Medicines, Inc. over competitors.
Bears Say
Clinical ConcernsResistance mutations were observed in a significant percentage of patients post-daraxonrasib monotherapy, raising concerns about durability.
Development ComplexityThe complexity of the Phase 3 development story for RVMD, especially with the initiation of a three-arm study, poses challenges.
Financial PerformanceRVMD 3Q25 EPS at -$1.61 was ~13% lower than consensus of -$1.42 based on higher than expected R&D and SG&A expenses.
Revolution Medicines News
RVMD FAQ
What was Revolution Medicines, Inc.’s price range in the past 12 months?
Revolution Medicines, Inc. lowest stock price was $29.17 and its highest was $63.15 in the past 12 months.
What is Revolution Medicines, Inc.’s market cap?
Revolution Medicines, Inc.’s market cap is $11.87B.
When is Revolution Medicines, Inc.’s upcoming earnings report date?
Revolution Medicines, Inc.’s upcoming earnings report date is Mar 02, 2026 which is in 114 days.
How were Revolution Medicines, Inc.’s earnings last quarter?
Revolution Medicines, Inc. released its earnings results on Nov 05, 2025. The company reported -$1.61 earnings per share for the quarter, missing the consensus estimate of -$1.421 by -$0.189.
Is Revolution Medicines, Inc. overvalued?
According to Wall Street analysts Revolution Medicines, Inc.’s price is currently Undervalued.
Does Revolution Medicines, Inc. pay dividends?
Revolution Medicines, Inc. does not currently pay dividends.
What is Revolution Medicines, Inc.’s EPS estimate?
Revolution Medicines, Inc.’s EPS estimate is -1.59.
How many shares outstanding does Revolution Medicines, Inc. have?
Revolution Medicines, Inc. has 193,319,810 shares outstanding.
What happened to Revolution Medicines, Inc.’s price movement after its last earnings report?
Revolution Medicines, Inc. reported an EPS of -$1.61 in its last earnings report, missing expectations of -$1.421. Following the earnings report the stock price went up 3.438%.
Which hedge fund is a major shareholder of Revolution Medicines, Inc.?
Currently, no hedge funds are holding shares in RVMD
Revolution Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$79.76 (29.94% Upside)
$79.76 (29.94% Upside)
Blogger Sentiment
Bullish
RVMD Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 9.1%
Last 30 Days ▲ 9.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.23%
12-Months-Change
Fundamentals
Return on Equity
-60.76%
Trailing 12-Months
Asset Growth
27.73%
Trailing 12-Months
Company Description
Revolution Medicines, Inc.
Revolution Medicines, Inc. (RVMD) is a biotechnology company that operates in the pharmaceutical sector, focusing on the discovery and development of novel targeted therapies for cancer. The company is particularly known for its precision oncology approach, targeting specific genetic mutations and pathways that drive cancer growth and progression. Revolution Medicines' core products are centered around inhibiting critical signaling pathways, such as the RAS and mTOR pathways, which are implicated in various types of cancers.
RVMD Company Deck
RVMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong progress in clinical programs and regulatory achievements for daraxonrasib, as well as a solid financial position supported by strategic partnerships. However, these positive developments were somewhat offset by increased operating expenses and significant net losses.View all RVMD earnings summariesRVMD Stock 12 Month Forecast
Average Price Target
$79.76
▲(29.94% Upside)
Technical Analysis
Corcept Therapeutics
―
Ionis Pharmaceuticals
―
Blueprint Medicines
―
Legend Biotech
―
Vaxcyte
―
Ownership Overview
6.40% Insiders
26.68% Mutual Funds
0.05% Other Institutional Investors
54.57% Public Companies and Individual Investors